Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor.
Ionotropic ATP receptors are widely expressed in mammalian CNS. Despite extensive functional characterization of neuronal homomeric P2X receptors in heterologous expression systems, the subunit composition of native central P2X ATP-gated channels remains to be elucidated. P2X4 and P2X6 are major central subunits with highly overlapping mRNA distribution at both regional and cellular levels. When expressed alone in Xenopus oocytes, P2X6 subunits do not assemble into surface receptors responsive to ATP applications. On the other hand, P2X4 subunits assemble into bona fide ATP-gated channels, slowly desensitizing and weakly sensitive to the partial agonist alpha,beta-methylene ATP and to noncompetitive antagonists suramin and pyridoxal-5-phosphate-6-azophenyl-2',4'-disulfonic acid. We demonstrate here that the coexpression of P2X4 and P2X6 subunits in Xenopus oocytes leads to the generation of a novel pharmacological phenotype of ionotropic ATP receptors. Heteromeric P2X4+6 receptors are activated by low-micromolar alpha, beta-methylene ATP (EC50 = 12 microM) and are blocked by suramin and by Reactive Blue 2, which has the property, at low concentrations, to potentiate homomeric P2X4 receptors. The assembly of P2X4 with P2X6 subunits results from subunit-dependent interactions, as shown by their specific copurification from HEK-293 cells transiently transfected with various epitope-tagged P2X channel subunits. Our data strongly suggest that the numerous cases of neuronal colocalizations of P2X4 and P2X6 subunits observed in mammalian CNS reflect the native expression of heteromeric P2X4+6 channels with unique functional properties.
Lê
K T
KT
Cell Biology of Excitable Tissue Group, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4.
Babinski
K
K
Séguéla
P
P
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002412:Cations / Q000378:metabolism; D002478:Cells, Cultured; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D007668:Kidney / Q000166:cytology; D009479:Neuropeptides / Q000737:chemistry / Q000502:physiology; D009865:Oocytes / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011522:Protons; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D018048:Receptors, Purinergic P2 / Q000737:chemistry* / Q000502:physiology*; D058848:Receptors, Purinergic P2X4; D013498:Suramin / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology; D014982:Xenopus laevis; D015032:Zinc / Q000494:pharmacology
D000970:Antineoplastic Agents; D002412:Cations; D004791:Enzyme Inhibitors; D009479:Neuropeptides; C548226:P2RX4 protein, human; D010975:Platelet Aggregation Inhibitors; D011522:Protons; D018048:Receptors, Purinergic P2; D058848:Receptors, Purinergic P2X4; D014227:Triazines; C110590:purinoceptor P2X6; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; C012842:Cibacron Blue F 3GA; D011732:Pyridoxal Phosphate; D013498:Suramin; D000255:Adenosine Triphosphate; D015032:Zinc; C002630:alpha,beta-methyleneadenosine 5'-triphosphate